clinical trial · NCT06219733
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
MedPacto, Inc.·phase2·withdrawn
DermoidVactosertibImatinib
brief summary
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
started
Jun 1, 2021
primary completion
May 23, 2022
completion
May 23, 2022
last updated
Dec 9, 2024
detailed description
This is an open-label, multi-center, randomized controlled study to evaluate the safety and efficacy of vactosertib 200 mg BID in combination with imatinib versus imatinib alone.
official title
A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared with Imatinib Monotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol